Yunnan Walvax Biotechnology, a vaccine company, obtained a 51% stake in Shanghai Fengmao Biotechnology Co. Walvax will establish subsidiaries of Fengmao to produce five monoclonal antibodies and a sustained-release version of the anemia treatment EPO. Walvax will invest 102 million RMB ($16 million), in a combination of cash and technology, to obtain control of Fengmao. More details.... Stock Symbol: (SHE: 300142) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});